Advertisement
Advertisement
U.S. markets close in 6 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Exact Sciences Corporation (EXAS)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
52.85-1.15 (-2.14%)
As of 03:54PM EDT. Market open.
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Williams %R

Williams %R

Previous Close54.00
Open54.74
Bid52.31 x 900
Ask52.36 x 800
Day's Range50.28 - 55.59
52 Week Range46.15 - 133.99
Volume1,341,368
Avg. Volume2,083,517
Market Cap9.298B
Beta (5Y Monthly)1.23
PE Ratio (TTM)N/A
EPS (TTM)-4.32
Earnings DateJul 26, 2022 - Aug 01, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est99.44
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for EXAS

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Exact Sciences Corporation
    Analyst Report: Exact Sciences CorporationExact Sciences Corporation, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact’s Cologuard screening test, a non-invasive stool-based DNA test, is a pre-cancer screening test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a genetic-based treatment selection test for breast, prostate, and colon cancers. With the acquisitions of Base Genomics and Thrive Earlier Detection, Exact is building a multi-cancer early screening test to detect over 14 cancers, a test that would be one of earliest entrants in multi-cancer liquid biopsy cancer screening.
    Rating
    Fair Value
    Economic Moat
    22 days agoMorningstar
View more
Advertisement
Advertisement